Literature DB >> 19434438

Very late relapses in glioblastoma long-term survivors.

Oliver Bähr, Ulrich Herrlinger, Michael Weller, Joachim P Steinbach.   

Abstract

Long-term survival of patients with histologically confirmed glioblastoma is a rare event with figures in the range of 2-3% for 5-year survival (Scott et al. in Ann Neurol 46:183-188, 1999; McLendon and Halperin in Cancer 98:1745-1748, 2003; Krex et al. in Brain 130:2596-2606, 2007). Prognosis and further clinical course of these patients beyond 5 years after diagnosis are in essence unknown with only anecdotal reports of patients surviving for 10 years or more (Salvati et al. J Neurooncol 36:61-64, 1998). We here report on the extended follow-up (mean, 139.4 months) of a cohort of glioblastoma long-term survivors. Very late relapses occurred in many patients even after more than 10 years of progression-free survival.

Entities:  

Mesh:

Year:  2009        PMID: 19434438     DOI: 10.1007/s00415-009-5167-6

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  5 in total

1.  Surviving glioblastoma for more than 5 years: the patient's perspective.

Authors:  J P Steinbach; H-P Blaicher; U Herrlinger; W Wick; T Nägele; R Meyermann; M Tatagiba; M Bamberg; J Dichgans; H-O Karnath; M Weller
Journal:  Neurology       Date:  2006-01-24       Impact factor: 9.910

2.  Which glioblastoma multiforme patient will become a long-term survivor? A population-based study.

Authors:  J N Scott; N B Rewcastle; P M Brasher; D Fulton; J A MacKinnon; M Hamilton; J G Cairncross; P Forsyth
Journal:  Ann Neurol       Date:  1999-08       Impact factor: 10.422

Review 3.  Long-term survival in patients with supratentorial glioblastoma.

Authors:  M Salvati; L Cervoni; M Artico; R Caruso; F M Gagliardi
Journal:  J Neurooncol       Date:  1998-01       Impact factor: 4.130

Review 4.  Long-term survival with glioblastoma multiforme.

Authors:  Dietmar Krex; Barbara Klink; Christian Hartmann; Andreas von Deimling; Torsten Pietsch; Matthias Simon; Michael Sabel; Joachim P Steinbach; Oliver Heese; Guido Reifenberger; Michael Weller; Gabriele Schackert
Journal:  Brain       Date:  2007-09-04       Impact factor: 13.501

5.  Is the long-term survival of patients with intracranial glioblastoma multiforme overstated?

Authors:  Roger E McLendon; Edward C Halperin
Journal:  Cancer       Date:  2003-10-15       Impact factor: 6.860

  5 in total
  10 in total

Review 1.  Living longer with adult high-grade glioma: setting a research agenda for patients and their caregivers.

Authors:  Bethany Russell; Anna Collins; Michael Dally; Anthony Dowling; Michelle Gold; Michael Murphy; Jennifer Philip
Journal:  J Neurooncol       Date:  2014-07-01       Impact factor: 4.130

2.  Predicting distress among people who care for patients living longer with high-grade malignant glioma.

Authors:  B Russell; A Collins; A Dowling; M Dally; M Gold; M Murphy; J Burchell; J Philip
Journal:  Support Care Cancer       Date:  2015-04-25       Impact factor: 3.603

3.  Neurocognitive training in patients with high-grade glioma: a pilot study.

Authors:  Marco Ronald Hassler; Katarzyna Elandt; Matthias Preusser; Johann Lehrner; Petra Binder; Karin Dieckmann; Andrea Rottenfusser; Christine Marosi
Journal:  J Neurooncol       Date:  2009-09-10       Impact factor: 4.130

4.  Dual targeting of glioblastoma with chimeric antigen receptor-engineered natural killer cells overcomes heterogeneity of target antigen expression and enhances antitumor activity and survival.

Authors:  Sabrina Genßler; Michael C Burger; Congcong Zhang; Sarah Oelsner; Iris Mildenberger; Marlies Wagner; Joachim P Steinbach; Winfried S Wels
Journal:  Oncoimmunology       Date:  2015-12-21       Impact factor: 8.110

5.  Neurological outcome of long-term glioblastoma survivors.

Authors:  Andreas F Hottinger; Hannah Yoon; Lisa M DeAngelis; Lauren E Abrey
Journal:  J Neurooncol       Date:  2009-06-26       Impact factor: 4.130

6.  Long Term Survival in Patients Suffering from Glio-blastoma Multiforme: A Single-Center Observational Cohort Study.

Authors:  Daniele Armocida; Alessandro Pesce; Federico Di Giammarco; Alessandro Frati; Antonio Santoro; Maurizio Salvati
Journal:  Diagnostics (Basel)       Date:  2019-11-30

Review 7.  A narrative review of research progress on drug therapies for glioblastoma multiforme.

Authors:  Xiangjin Zheng; Qin Tang; Liwen Ren; Jinyi Liu; Wan Li; Weiqi Fu; Jinhua Wang; Guanhua Du
Journal:  Ann Transl Med       Date:  2021-06

8.  Tumor Recurrence in a Glioblastoma Patient after Discontinuation of Prolonged Temozolomide Treatment.

Authors:  Wei-Lung Tseng; Hsu-Hsien Hsu; Yun Chen; Sheng-Hong Tseng
Journal:  Asian J Neurosurg       Date:  2017 Oct-Dec

Review 9.  CAR-Engineered NK Cells for the Treatment of Glioblastoma: Turning Innate Effectors Into Precision Tools for Cancer Immunotherapy.

Authors:  Michael C Burger; Congcong Zhang; Patrick N Harter; Annette Romanski; Florian Strassheimer; Christian Senft; Torsten Tonn; Joachim P Steinbach; Winfried S Wels
Journal:  Front Immunol       Date:  2019-11-14       Impact factor: 7.561

10.  A Computational Framework to Identify Biomarkers for Glioma Recurrence and Potential Drugs Targeting Them.

Authors:  Shuzhi Ma; Zhen Guo; Bo Wang; Min Yang; Xuelian Yuan; Binbin Ji; Yan Wu; Size Chen
Journal:  Front Genet       Date:  2022-01-17       Impact factor: 4.599

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.